When We Talks

Seagen inks deal with Dutch biotech to develop and commercialize drug candidate – GeekWire

Seagen has inked a deal to develop, manufacture and commercialize an experimental immuno-oncology agent from Lava Therapeutics, a biotech company based in Utrecht, Netherlands. Seagen will pay Lava $50 million upfront to exclusively license Lava-1223, a “bispecific T cell engager” designed to direct certain T cells to tumors via the target EGFR on cancer cells. Seagen will also pay Lava up to $650 million in future milestone payments and has the option to exclusively negotiate rights to apply Lava’s platform to two other tumor targets. The deal, announced Monday, comes a month after talks over a potential acquisition of Bothell, Wash.-based Seagen by Merck reportedly stalled over the price.

Source link

Related posts

Seattle startup ModusBox spins out PortX into new financial services company and raises $10M – GeekWire

Effie Weber

Cosmetic treatment review platform RealSelf lays off 11 employees – GeekWire

Effie Weber

NASA resets moon rocket’s launch for Saturday as it analyzes data

Effie Weber